The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group

Table 2 Patient characteristics by study

Characteristics	7401 (n = 38)	7918 (n = 9)	8302 (n = 30)	8409 (n = 1)	9006 (n = 32)	9305 (n = 3)	9602 (n = 13)	9806 (n = 27)	Total (N = 153)
Gender
Male	27 (71%)	4 (44%)	22 (73%)	1 (100%)	20 (63%)	1 (33%)	5 (38%)	18 (67%)	98 (64%)
Female	11 (29%)	5 (56%)	8 (27%)	0	12 (38%)	2 (67%)	8 (62%)	9 (33%)	55 (36%)
Race
White	35 (92%)	8 (89%)	28 (93%)	1 (100%)	30 (94%)	3 (100%)	13(100%)	26 (96%)	144 (94%)
Hispanic	2 (5%)	0	0	0	0	0	0	1 (4%)	3 (2%)
Black	1 (3%)	1 (11%)	1 (3%)	0	2 (6%)	0	0	0	5 (3%)
Other	0	0	1 (3%)	0	0	0	0	0	1 (1%)
Neuro. Function (Symptoms)
None/Minor	16 (42%)	3 (33%)	13 (43%)	0	23 (72%)	0	7 (54%)	19 (70%)	84 (54%)
Moderate	13 (34%)	5 (56%)	16 (53%)	1 (100%)	9 (28%)	3 (100%)	6 (46%)	8 (30%)	59 (38%)
Major/Severe	8 (21%)	1 (11%)	1 (3%)	0	0	0	0	0	11 (7%)
Missing	1 (3%)	0	0	0	0	0	0	0	1 (1%)
KPS
≤ 60	11 (29%)	1 (11%)	2 (7%)	0	1 (3%)	0	0	2 (7%)	17 (11%)
70–80	13 (34%)	6 (67%)	19 (63%)	1 (100%)	12 (38%)	0	6 (46%)	10 (37%)	67 (44%)
90–100	14 (37%)	2 (22%)	9 (30%)	0	19 (59%)	3 (100%)	7 (54%)	15 (56%)	69 (45%)
Prior Surgery
Biopsy	5 (13%)	0	1 (3%)	0	1 (3%)	0	0	3 (11%)	10 (7%)
Part. Resect.	21 (55%)	5 (56%)	22 (73%)	1 (100%)	15 (47%)	1 (33%)	10 (77%)	15 (56%)	90 (59%)
Tot. Resect.	11 (29%)	4 (44%)	7 (23%)	0	16 (50%)	2 (67%)	3 (23%)	8 (30%)	51 (33%)
Unknown	1 (3%)	0	0	0	0	0	0	1 (4%)	2 (1%)
RPA
III	6 (16%)	1 (11%)	3 (10%)	0	7 (22%)	2 (67%)	4 (31%)	6 (22%)	29 (19%)
IV	15 (39%)	3 (33%)	13 (43%)	1 (100%)	16 (50%)	1 (33%)	3 (23%)	11 (41%)	63 (41%)
V	17 (45%)	5 (56%)	14 (47%)	0	9 (28%)	0	6 (46%)	10 (37%)	61 (40%)

ISSN: 1748-717X